MedTrace Logo

Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors

NCT01050413 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2010-06-03

No results posted yet for this study

Summary

This study aimed to evaluate serum thymidine kinase 1 (TK1) activity as a marker for solid tumors and more specifically in: preoperative testing for prediction of disease recurrence and survival; follow-up after surgical removal of the original tumor for early detection of disease recurrence and in monitoring therapy as a surrogate marker of tumor response.

Conditions

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-12-31
Completion
2011-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050413 on ClinicalTrials.gov